ArticleProteoglycan research2025
The Role of Decorin in the Ocular Surface: Structure, Function, and Therapeutic Potential.
Article in Proteoglycan research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Introduction to the Special Issue on Proteoglycan and Glycosaminoglycan Biology.Proteoglycan research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The ocular surface, comprising the cornea, conjunctiva, and sclera, relies on a complex extracellular matrix (ECM) for structural support and functional integrity. Decorin (DCN), a small leucine-rich proteoglycan, a key ECM component involved in collagen fibrillogenesis, growth factor modulation, and cellular regulation, is essential for maintaining corneal transparency, wound healing, and preventing pathological fibrosis. DCN interacts with various target molecules, including transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor (EGFR), influencing critical processes, such as cell proliferation, inflammation, and angiogenesis. These interactions underscore DCN's therapeutic potential in ocular disorders like corneal scarring, pterygium, and keratoconus. This review explores the structure, expression, and functions of DCN in the ocular surface, emphasizing its regulatory mechanisms and therapeutic potential. Recent advancements include gene therapy approaches, sustained release systems, and topical applications, each demonstrating significant promise in treating ocular surface diseases. Additionally, the review highlights the importance of DCN in ocular disorders, including congenital stromal corneal dystrophy (CSCD), KC, and pterygium. This review aims to elucidate the multifaceted roles of DCN, paving the way for innovative therapeutic strategies in ocular surface therapy. Future directions for DCN research involve advanced delivery mechanisms, gene editing technologies, and expanded studies on other ocular surfaces.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.